Cargando…
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Chimeric antigen receptor (CAR) T cells targeting CD19 have been successful treating patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL) and B cell lymphomas. However, relapse after CAR T cell therapy is still a challenge. In addition, preclinical and early clinical studies t...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058784/ https://www.ncbi.nlm.nih.gov/pubmed/32185132 http://dx.doi.org/10.3389/fonc.2020.00262 |